Anagliptin/Metformin Hydrochloride

安奈格列汀/盐酸二甲双胍

Report date: 2026/03/30 17:02:26

Base Information

Drug NameAnagliptin/Metformin Hydrochloride
Drug Alias Name安奈格列汀+二甲双胍Anagliptin and Metformin HydrochlorideAnagliptin and Metformin二甲双胍/安奈格列汀Anagliptin•Metformin +[14] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2018/09/21
Country/TerritoryJapan
CombinationsYes AnagliptinMetformin Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSanwa Kagaku Kenkyusho Co LtdSuzuken
China Registration ClassN/A

Develop Information

Active CompaniesSanwa Kagaku Kenkyusho Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD
Related LinksN/A